Date: 2012-10-04
Type of information: R&D agreement
Compound: preclinical compounds for the drug optimization and selection program for Intellect’s antibody drug conjugate (ADC), CONJUMAB-A
Company: iNovacia (Sweden) Intellect Neurosciences (USA)
Therapeutic area: Ophtalmological diseases
Type agreement: R&D
Action mechanism: The CONJUMAB platform empowers monoclonal antibodies targeting amyloidogenic proteins with additional neuroprotective properties by combining them chemically with a small molecule such as an antioxidant. CONJUMAB-A, the first compound from this platform, is a monoclonal antibody specific for beta amyloid conjugated to melatonin which is recognized as a potent antioxidant. Beta amyloid, when it accumulates in the retina of the eye, causes damage by oxidative stress. The conjugate is anticipated to increase the therapeutic window for melatonin to protect retinal epithelial cells, promote clearance of beta-amyloid away from sites of damage and avoid potential off-target side-effects. CONJUMAB-A may also have potential applications for diabetic retinopathy, glaucoma, traumatic brain injury, and Alzheimer’s disease.
Disease: age related macular degeneration
Details: Intellect Neurosciences, a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies, and iNovacia, a subsidiary to Kancera AB leading experts in compound screening, have entered into a Research Service Agreement to evaluate preclinical compounds for the drug optimization and selection program for Intellect’s antibody drug conjugate, CONJUMAB-A, currently being developed for age related macular degeneration (AMD).
CONJUMAB-A, is anticipated to counter the neurotoxic effects of amyloid beta accumulation and to promote its clearance away from tissues where it causes damage. iNovacia will perform a series of in vitro tests to evaluate compounds so that Intellect can select an optimal drug candidate for further development.
Financial terms:
Latest news:
